Hemant Bakhru

The portfolio being bought is largely oral products, so I don't think the margins will be huge, but at least they have something to get them going in the U.S..

mergers-acquisitions

Large-cap Indian pharma companies are predominantly dollar exposed, emerging-market investors who right now want to avoid risk and invest in assets that are more exposed to the U.S. economy as against emerging markets will naturally choose some of these Indian pharma names.